Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether siltuximab changes clinical improvement D28b compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.97 [0.79, 1.18]
1 study · 148 participants
Very low

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19

Siltuximab may leads to higher WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.97 [1.07, 3.63]
1 study · 148 participants
Low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether siltuximab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.35 [0.54, 3.36]
1 study · 148 participants
Very low

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.58 [0.74, 3.38]
1 study · 148 participants
Very low

Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.29 [0.64, 2.62]
1 study · 148 participants
Low